ADYX (Adynxx) Ending Cash Position: $0.58 Mil (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADYX Adynxx Inc ADYX
16 GF Score
Price $0.00
View Full Analysis

What is Adynxx Ending Cash Position?

Adynxx ADYX 16 Ending Cash Position is $0.58 Mil as of Sep. 2019. GuruFocus rates ADYX with a GF Score™ of 16/100.

Adynxx's Ending Cash Position for the quarter that ended in Sep. 2019 was $0.58 Mil.

Adynxx's quarterly Ending Cash Position declined from Mar. 2019 ($7.73 Mil) to Jun. 2019 ($0.28 Mil) but then increased from Jun. 2019 ($0.28 Mil) to Sep. 2019 ($0.58 Mil).

Adynxx's annual Ending Cash Position declined from Dec. 2016 ($5.58 Mil) to Dec. 2017 ($2.18 Mil) but then increased from Dec. 2017 ($2.18 Mil) to Dec. 2018 ($8.88 Mil).

Adynxx Ending Cash Position Related Terms

Adynxx Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Adynxx's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adynxx Ending Cash Position Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.77 26.08 5.58 2.18 8.88

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.10 8.88 7.73 0.28 0.58
ADYX
16GF Score
Adynxx Inc ADYX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adynxx Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Adynxx's Ending Cash Position for the fiscal year that ended in Dec. 2018 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.181+6.699
=8.88

Adynxx's Ending Cash Position for the quarter that ended in Sep. 2019 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.278+0.306
=0.58

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.58 Mil mean?
Adynxx (ADYX) has a Ending Cash Position of $0.58 Mil as of Sep. 2019. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adynxx and its competitors.
Is Adynxx's Ending Cash Position too high?
Adynxx's current Ending Cash Position is $0.58 Mil. Overall, Adynxx has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Adynxx's Ending Cash Position compare to TRPX and MITI?
Adynxx's Ending Cash Position of $0.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adynxx and its competitors. Adynxx's current Ending Cash Position is $0.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adynxx stock overvalued right now?
Adynxx (ADYX) has a current Ending Cash Position of $0.58 Mil. The current Ending Cash Position is $0.58 Mil. Adynxx's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Adynxx (ADYX), the current Ending Cash Position is $0.58 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adynxx Business Description

Address 100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
16GF Score

Get the complete analysis for ADYX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price